Professional
Added to YB: 2025-10-22
Pitch date: 2025-09-30
CRSP [neutral]
CRISPR Therapeutics AG
-12.46%
current return
Author Info
No bio for this author
Company Info
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Market Cap
$5.3B
Pitch Price
$64.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.30
P/E
-9.91
EV/Sales
92.31
Sector
Biotechnology
Category
growth
Contrarius Global Equity Fund Portfolio Holding: CRISPR Therapeutics AG
CRSP (holding update): First FDA-approved CRISPR gene therapy (Casgevy) for sickle cell disease at $2.2M per treatment vs $4-6M lifetime costs. 40% profit share with Vertex (paid $1.1B total). 100K US SCD patients, 5 clinical + 10 preclinical programs. $5.9B market cap, $1.7B net cash. CEO targets $100B+ platform company.
Read full article (2 min)